Advisory Services Network’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.8K Buy
+2,637
New +$41.6K ﹤0.01% 3097
2025
Q4
Sell
-1,543
Closed -$22.6K 1831
2025
Q3
$22.6K Buy
+1,543
New +$26.4K ﹤0.01% 2891
2023
Q2
Sell
-500
Closed -$1.66K 1456
2023
Q1
$1.66K Hold
500
﹤0.01% 3488
2022
Q4
$1.94K Buy
+500
New +$1.54K ﹤0.01% 3442
2021
Q3
Sell
-500
Closed -$1K 1404
2021
Q2
$1K Buy
+500
New +$880 ﹤0.01% 3410
2021
Q1
Sell
-1,500
Closed -$3K 1301
2020
Q4
$3K Buy
+1,500
New +$3.15K ﹤0.01% 2843
2020
Q2
Sell
-3,000
Closed -$9K 1069
2020
Q1
$9K Hold
3,000
﹤0.01% 2223
2019
Q4
$12K Buy
3,000
+1,000
+50% +$4.36K ﹤0.01% 2252
2019
Q3
$8K Hold
2,000
﹤0.01% 2237
2019
Q2
$8K Hold
2,000
﹤0.01% 2235
2019
Q1
$8K Hold
2,000
﹤0.01% 1912
2018
Q4
$5K Hold
2,000
﹤0.01% 1994
2018
Q3
$12K Sell
2,000
-750
-27% -$4.32K ﹤0.01% 1750
2018
Q2
$17K Buy
2,750
+1,050
+62% +$5.23K ﹤0.01% 1592
2018
Q1
$8K Buy
1,700
+1,000
+143% +$3.98K ﹤0.01% 1934
2017
Q4
$2K Buy
+700
New +$1.96K ﹤0.01% 2333

Other funds holding ADMA

Advisory Services Network's ADMA Position: Q1 2026 in Review

Advisory Services Network opened a new position in ADMA Biologics (ADMA) in Q1 2026: 2,637 shares worth $23.8K. The stake represents ﹤0.01% of the portfolio and ranks #3097 among its holdings. This is a return to the name: Advisory Services Network previously reported a position in ADMA as recently as Q3 2025.

Advisory Services Network first reported a position in ADMA in Q4 2017 and has held it in 16 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Advisory Services Network held 2,637 shares of ADMA Biologics worth $23.8K as of Q1 2026.
  • ADMA Biologics was a new Advisory Services Network position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2026, its #3097 holding.
  • Advisory Services Network first reported a position in ADMA Biologics in Q4 2017 and has held it in 16 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.